COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 18 for:    "Bone Marrow Cancer" | "interferons"
Previous Study | Return to List | Next Study

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera (MITHRIDATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04116502
Recruitment Status : Recruiting
First Posted : October 4, 2019
Last Update Posted : March 30, 2020
MPN Voice
National Cancer Institute, France
Information provided by (Responsible Party):
University of Birmingham

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 1, 2026
Estimated Study Completion Date : February 1, 2028